ClinicalTrials.gg
CompletedNCT00507442EVOLUTIONUpdated Jul 26, 2013Results posted

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

A Phase 1/2 interventional study of VELCADE (bortezomib) and dexamethasone in Multiple Myeloma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-26.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 171 studies testing cyclophosphamide in Multiple Myeloma — 15 open to participants now, 27 under way, 1 of them phase 3. Cyclophosphamide · Multiple Myeloma.

Enrollment
24th of 167
158 · median 41
Started
2007
with 5 others
Phase 1/2
20 of 171
2 open now
Registered
37th of 171
by date

Among the 171 studies testing cyclophosphamide in Multiple Myeloma, this one is the 24th largest by enrollment of the 167 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 1/2, and was the 37th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 171 studies testing cyclophosphamide in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies testing cyclophosphamide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with multiple myeloma who have received no prior treatment. This study will evaluate whether the addition of Revlimid to VELCADE and Dexamethasone will increase the complete response (CR)/ very good partial response (VGPR) rate.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Treatment for patients with multiple myeloma
  • who have received no prior treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written
  • Male or female subject 18 years of age or older
  • A Performance Status score of ≥50% ( Performance Status score ≤2)
  • Subjects must have symptomatic myeloma or asymptomatic myeloma with myeloma-related organ damage
  • Diagnosed Multiple myeloma
  • Subjects must have requiring systemic therapy
  • Subjects must not have been treated previously with any systemic therapy for multiple myeloma
  • Two weeks must have elapsed since the date of the last radiotherapy treatment
  • Women of must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 to 14 days prior to therapy and repeated within 24 hours before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of (1 highly effective method and 1 additional effective method) used at the same time, beginning at least 4 weeks before initiation of Revlimid treatment. Women must also agree to ongoing pregnancy testing
  • Men must agree to not father a child and agree to use a latex condom during therapy and for 4 weeks after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential
  • All subjects must agree to comply with the requirements of the RevAssistSM program

Exclusion criteria

Exclusion Criteria:

  • History of allergy to any of the study medications, their analogues, or in the various formulations
  • ≥Grade 2 peripheral neuropathy on clinical examination
  • Myocardial infarction within 6 months prior to enrollment or Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or conduction system abnormalities.
  • Female subject who is pregnant or breast-feeding
  • Clinically relevant active infection or serious comorbid medical conditions
  • Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at unacceptable risk if he/she were to participate in the study. This includes but is not limited to serious medical or psychiatric illness likely to interfere with participation in this clinical study
  • Active prior diagnosed or treated within the last 3 years
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    VDR

    VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)

    Drug: VELCADE (bortezomib) · Drug: dexamethasone · Drug: Revlimid (lenalidomide)

  • Experimental
    VDCR

    VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)

    Drug: VELCADE (bortezomib) · Drug: dexamethasone · Drug: cyclophosphamide · Drug: Revlimid (lenalidomide)

  • Experimental
    VDC

    VELCADE (bortezomib), dexamethasone, cyclophosphamide

    Drug: VELCADE (bortezomib) · Drug: dexamethasone · Drug: cyclophosphamide

  • Experimental
    VDC-mod

    Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide

    Drug: VELCADE (bortezomib) · Drug: dexamethasone · Drug: cyclophosphamide

Interventions

  • bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).

  • dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop

  • cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop

  • lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm) lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)

06

What researchers measure

Primary outcomes

  1. Number of Patients With Combined Complete Response and Very Good Partial Response

    Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Very good partial response requires serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 h

    Time frame: Up to 48 weeks or until disease progression

Secondary outcomes

  1. Number of Patients With Adverse Events (AEs)

    Evaluate the safety and tolerability of the combination therapy

    Time frame: From first dose of study drug through the 30 day post-treatment AE assessment visit

  2. Number of Patients With Overall Response

    Overall Response includes complete response and partial response. Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Partial response requires at least 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by at least 90% or to \< 200 mg per 24 hour.

    Time frame: Up to 48 weeks or until disease progression

  3. Number of Patients With Stringent Complete Response Rate

    Stringent Complete Response is defined as complete response plus normal free light chain (kappa/lambda) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Time frame: Up to 48 weeks or until disease progression

  4. Number of Patients With Complete Response Rate + Near Complete Response Rate

    Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Near Complete response requires positive immunofixation on the serum and/or urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow.

    Time frame: Up to 48 weeks or until disease progression

  5. Duration of Response

    Duration of response is the time from date of first documented confirmed response to date of first documented progressive disease. A confirmed response is a response that has been observed on at least two consecutive assessments. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.

    Time frame: Up to 48 weeks or until disease progression

  6. Time to Disease Progression

    Time to disease progression is defined as time from the date of randomization to the date of first documented progressive disease. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.

    Time frame: Up to 48 weeks or until disease progression

  7. Time to Response

    Time to response is defined as time from date of randomization to the date of the first documentation of a confirmed response. confirmed response is a response that has been observed on at least two consecutive assessments.

    Time frame: Up to 48 weeks or until disease response

  8. Progression-free Survival

    Progression-free survival is defined as time from the date of randomization to the date of the first documented progressive disease or death. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.

    Time frame: Up to 48 weeks or until disease progression/death

  9. Probability of 1-year Survival

    Time frame: survival probability at 1 year after randomization

  10. Overall Survival

    Overall survival is defined as time from the date of randomization to the date of death

    Time frame: Up to 48 weeks or until death

07

Results

Posted Dec 29, 2011

Participant flow

Participant flow — Overall Study
MilestoneV-DRVDCRV-DCVDC-mod
Started42663317
Completed26391812
Not completed1627155
Withdrew: Adverse event81141
Withdrew: Protocol violation0100
Withdrew: Lost to follow-up0010
Withdrew: Physician decision0241
Withdrew: Progressive disease2420
Withdrew: Withdrawal by subject4421
Withdrew: Other2522

Outcome measures

PrimaryNumber of Patients With Combined Complete Response and Very Good Partial Response

Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Very good partial response requires serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 h

Time frame:
Up to 48 weeks or until disease progression
Reported as:
Number · participants
Number of Patients With Combined Complete Response and Very Good Partial Response
participantsV-DRVDCRV-DCVDC-mod
Number of Patients With Combined Complete Response and Very Good Partial Response2123139
SecondaryNumber of Patients With Adverse Events (AEs)

Evaluate the safety and tolerability of the combination therapy

Time frame:
From first dose of study drug through the 30 day post-treatment AE assessment visit
Reported as:
Number · participants
Number of Patients With Adverse Events (AEs)
participantsV-DRVDCRV-DCVDC-mod
Number of Patients With Adverse Events (AEs)42653317
SecondaryNumber of Patients With Overall Response

Overall Response includes complete response and partial response. Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Partial response requires at least 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by at least 90% or to \< 200 mg per 24 hour.

Time frame:
Up to 48 weeks or until disease progression
Reported as:
Number · participants
Number of Patients With Overall Response
participantsV-DRVDCRV-DCVDC-mod
Number of Patients With Overall Response35352417
SecondaryNumber of Patients With Stringent Complete Response Rate

Stringent Complete Response is defined as complete response plus normal free light chain (kappa/lambda) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

Time frame:
Up to 48 weeks or until disease progression
Reported as:
Number · participants
Number of Patients With Stringent Complete Response Rate
participantsV-DRVDCRV-DCVDC-mod
Number of Patients With Stringent Complete Response Rate7635
SecondaryNumber of Patients With Complete Response Rate + Near Complete Response Rate

Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Near Complete response requires positive immunofixation on the serum and/or urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow.

Time frame:
Up to 48 weeks or until disease progression
Reported as:
Number · participants
Number of Patients With Complete Response Rate + Near Complete Response Rate
participantsV-DRVDCRV-DCVDC-mod
Number of Patients With Complete Response Rate + Near Complete Response Rate1714108
SecondaryDuration of Response

Duration of response is the time from date of first documented confirmed response to date of first documented progressive disease. A confirmed response is a response that has been observed on at least two consecutive assessments. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.

Time frame:
Up to 48 weeks or until disease progression
Reported as:
Median · days
Duration of Response
daysV-DRVDCRV-DCVDC-mod
Duration of ResponseNA (302 to NA)NA (583 to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Disease Progression

Time to disease progression is defined as time from the date of randomization to the date of first documented progressive disease. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.

Time frame:
Up to 48 weeks or until disease progression
Reported as:
Median · days
Time to Disease Progression
daysV-DRVDCRV-DCVDC-mod
Time to Disease ProgressionNA (NA to NA)NA (631 to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Response

Time to response is defined as time from date of randomization to the date of the first documentation of a confirmed response. confirmed response is a response that has been observed on at least two consecutive assessments.

Time frame:
Up to 48 weeks or until disease response
Reported as:
Median · days
Time to Response
daysV-DRVDCRV-DCVDC-mod
Time to Response49 (43 to 175)50 (41 to 145)55 (42 to 302)49 (42 to 194)
SecondaryProgression-free Survival

Progression-free survival is defined as time from the date of randomization to the date of the first documented progressive disease or death. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.

Time frame:
Up to 48 weeks or until disease progression/death
Reported as:
Median · days
Progression-free Survival
daysV-DRVDCRV-DCVDC-mod
Progression-free SurvivalNA (356 to NA)631 (555 to NA)NA (778 to NA)NA (NA to NA)
SecondaryProbability of 1-year Survival
Time frame:
survival probability at 1 year after randomization
Reported as:
Number · percentage of patients
Probability of 1-year Survival
percentage of patientsV-DRVDCRV-DCVDC-mod
Probability of 1-year Survival10091.6100100
SecondaryOverall Survival

Overall survival is defined as time from the date of randomization to the date of death

Time frame:
Up to 48 weeks or until death
Reported as:
Median · days
Overall Survival
daysV-DRVDCRV-DCVDC-mod
Overall SurvivalNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over From first dose of any study drug to 30-day post-treatment adverse event assessment, up to 48 weeks and 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V-DR—17/42 (40.5%)41/42 (97.6%)
VDCR—26/66 (39.4%)65/66 (98.5%)
V-DC—7/33 (21.2%)33/33 (100%)
VDC-mod—7/17 (41.2%)17/17 (100%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventV-DRVDCRV-DCVDC-mod
SyncopeNervous system disorders0/421/660/332/17
Febrile neutropeniaBlood and lymphatic system disorders1/425/660/330/17
Urinary tract infection NOSInfections and infestations0/420/662/330/17
Hypotension NOSVascular disorders1/422/662/330/17
Pneumonia NOSInfections and infestations2/423/660/331/17
InfluenzaInfections and infestations0/420/660/331/17
Pneumonia streptococcalInfections and infestations0/420/660/331/17
Small intestinal obstruction NOSGastrointestinal disorders0/421/660/331/17
PyrexiaGeneral disorders2/423/661/331/17
WeaknessGeneral disorders0/420/660/331/17
Most frequent other events
Showing 10 of 56
Most frequent other events
EventV-DRVDCRV-DCVDC-mod
ConstipationGastrointestinal disorders26/4229/6616/337/17
Peripheral neuropathy NOSNervous system disorders14/4224/6615/339/17
NeutropeniaBlood and lymphatic system disorders8/4233/6617/338/17
Pain in limbMusculoskeletal and connective tissue disorders12/4222/6612/337/17
Peripheral sensory neuropathyNervous system disorders17/4226/669/331/17
CoughRespiratory, thoracic and mediastinal disorders16/4214/665/332/17
InsomniaPsychiatric disorders14/4221/669/336/17
Dizziness (excl vertigo)Nervous system disorders13/4218/664/333/17
Oedema lower limbGeneral disorders9/4219/668/335/17
RigorsGeneral disorders11/4214/665/332/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)V-DRVDCRV-DCVDC-modTotal
<=18 years00000
Between 18 and 65 years27422111101
>=65 years152412657
Age Continuous
Age Continuous(years)V-DRVDCRV-DCVDC-modTotal
Mean59.5 ± 8.7660.9 ± 8.9761.4 ± 8.3259.6 ± 9.1660.5 ± 8.75
Sex: Female, Male
Sex: Female, Male(Participants)V-DRVDCRV-DCVDC-modTotal
Female1828141070
Male243819788
Region of Enrollment
Region of Enrollment(participants)V-DRVDCRV-DCVDC-modTotal
United States42663317158
08

Study locations

2 sites
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Mayo Clinic
    Rochester, Minnesota 55904-0001, United States
09

References and documents

Publications

  • Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749. Epub 2012 Mar 15. PubMed 22422823 ↗
  • Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul;24(7):1350-6. doi: 10.1038/leu.2010.116. Epub 2010 May 27. PubMed 20508619 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Oct 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2007
First posted
Jul 26, 2007
Start
Aug 2007
Primary completionActual
Oct 2010
CompletionActual
Nov 2010
Results first posted
Dec 29, 2011
Last update
Jul 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00507442
Responsible party
Sponsor
First posted
Jul 26, 2007
Start date
Aug 2007
Primary completion
Oct 2010
Completion
Nov 2010
Results posted
Dec 29, 2011
Last update
Jul 26, 2013

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Lenalidomide

Start the discussion